News

For the second quarter of 2011, the company has generated net income of $2.73bn, compared to $2.44bn for the same period in the prior year. Net sales were

The new patent covers methods of PEGylating fusion proteins and multifunctional antibodies by the DNL technique. Immunomedics president and CEO Cynthia Sullivan said they believe PEGylation is an

TMC278 was approved in May 2011 by the US Food and Drug Administration, in combination with other antiretroviral (ARV) medications, for treatment of adults with HIV infection who

VELCADE is indicated for multiple myeloma (MM) and mantle cell lymphoma. The submission contains clinical data from the Phase III VISTA trial comparing the use of VELCADE based

For the second quarter of 2011, the company has generated net income of $13.08m, compared to $22.87m for the same period in 2010. ICON’s income from operations was

The Unifill ready-to-fill (prefilled) syringe is a primary drug container with passive safety features fully integrated within the glass barrel. With Unifill syringe, the undisclosed pharma firm is

Sun Pharma’s alfuzosin hydrochloride extended release tablets are the generic version of Sanofi-aventis’ Uroxatral extended release tablets. Uroxatral is approved to treat signs and symptoms of benign prostatic

Under the agreement, Lonza is responsible to produce materials for Phase 2 trial at its mammalian development and manufacturing plant. IMMUNE claims its human immunoglobulin monoclonal antibody Bertilimumab

The trial aims to evaluate the tolerability, pharmacokinetics (PK) and safety of GLPG0492 on muscle function in healthy volunteers. Earlier, in a Phase I study in healthy volunteers,